DOI: https://doi.org/10.32461/2226-3209.1.2018.178580

THE EFFECT OF CURCUMIN SUPPLEMENTATION ON LIPID PROFILES IN HEMODIALYSIS PATIENTS

Maryam Haji Nezhad, Akram Khoshki, Mostafa Rad

Abstract


Abstract. The aim of this study was to determine the effect of curcumin on systemic inflammation and
serum lipid profiles in hemodialysis patients. The aim of this study was to determine the effect of curcumin on systemic inflammation and serum lipid profiles in hemodialysis patients. Then, an experimental group received 80 mg of curcumin for 2 months and the control group received placebo. Before and after intervention, after 12 hours of fasting blood cc5, blood samples were taken from patients for triglyceride, cholesterol, HDL-C and LDL-C parameters. Data were then entered into SPSS 16 software and analyzed by Kolmogorov-Smirnov, Chi-square, Fisher test and T-test. According to the results of the analyzes, the results of the assumptions under study indicated that the supplementation of curcumin reduced serum LDL-C concentrations (P <0.05) and increased serum HDL-C (P = 0.003) in hemodialysis patients. Serum cholesterol and serum triglyceride in patients without hemodialysis are equal to (P> 0.05). The results of this study showed that curcumin supplement can be effective in preventing heart disease and can be used as a complementary therapy.
Keywords: Curcumin, Systemic inflammation, Hemodialysis, Serum lipid profile.


Full Text:

PDF

References


Fauci AS. Harrison's principles of internal medicine: McGraw-Hill, Medical Publishing Division New

York; 2008.

Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential

mechanisms. Journal of the American Society of Nephrology. 2006;17(8):2106-11.

Stewart GA, Gansevoort R, Mark PB, Rooney E, Mcdonagh TA, Dargie HJ, et al. Electrocardiographic

abnormalities and uremic cardiomyopathy. Kidney international. 2005;67(1):217-26.

Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, et al. Comparison of differing C-

reactive protein assay methods and their impact on cardiovascular risk assessment. The American journal of

cardiology. 2005;95(1):155-8.

Goldsmith DJ, Covic A. Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney

international. 2001;60(6):2059-78.

Marcus J, Sarnak MJ, Menon V, Verma S. Homocysteine lowering and cardiovascular disease risk: lost in

translation. Canadian Journal of Cardiology. 2007;23(9):707-10.

Saunders W. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and

chronic kidney disease. 2007.

Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Peritoneal dialysis

international. 2006;26(5):523-39.

Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end‐stage

renal disease: an emerging threat to patient outcome. Nephrology Dialysis Transplantation. 2003;18(7):1272-80.

SEYFI S, MOKHTARI A. Serum IL-6 level and associated factors: hemodialysis patients. 2008.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density

lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England journal of medicine.

;347(20):1557-65.

Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation

practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal

medicine. 2003;139(2):137-47.

Wanner C, Metzger T. C‐reactive protein a marker for all cause and cardiovascular mortality in

haemodialysis patients. Nephrology Dialysis Transplantation. 2002;17(suppl_8):29-32.

Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation,

nutrition, anemia, and clinical outcome in hemodialysis patients. The American journal of clinical nutrition.

;80(2):299-307.

Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis. Arteriosclerosis,

thrombosis, and vascular biology. 1999;19(10):2348-54.

Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human

peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82(2):513-20.

Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human

endothelial cells. Circulation. 20.8-2165:)18(102;00

Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in

the arterial intima. Arteriosclerosis, thrombosis, and vascular biology. 2000;20(9):2094-9.

Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. The American

journal of cardiology. 2004;93(2):221-5.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of

inflammation and cardiovascular disease. Circulation. 2 :511-499:(3)107;003.

Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H, Yamaguchi M, et al. High sensitivity C-

reactive protein in asthma. European Respiratory Journal. 2006;27(5):908-12.

Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic

dialysis patients. Nephrology Dialysis Transplantation. 1999;14(8):1956-60.

Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, et al. UK Consensus Conference on

early chronic kidney disease—6 and 7 February 200 .7Nephrology Dialysis Transplantation. 2007;22(9):2455-7.

Owen WF. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney

international. 1998;54(2):627-36.

Selim G, Stojceva-Taneva O, Zafirovska K, Sikole A, Gelev S, Dzekova P, et al. Inflammation predicts

all-cause and cardiovascular mortality in haemodialysis patients. Prilozi/Makedonska akademija na naukite i

umetnostite, Oddelenie za bioloski i medicinski nauki= Contributions/Macedonian Academy of Sciences and

Arts, Section of Biological and Medical Sciences. 2006;27(1):133-44.

Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and

cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases. 2000;35(3):469-76.

Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk

and mortality in hemodialysis patients. Kidney international. 1999;55(2):648-5.8

Shahbazian H, Atrian A, Yazdanpanah L, Lashkarara GR, Mohtashami AZ. Anti-inflammatory effect of

simvastatin in hemodialysis patients. Jundishapur journal of natural pharmaceutical products. 2015;10(1).

Donmez L, Gokkoca Z, Dedeoglu N. Disability and its effects on quality of life among older people

living in Antalya city center, Turkey. Archives of gerontology and geriatrics. 2005;40(2):213-23.

Nyman A, Josephsson S, Isaksson G. Being part of an enacted togetherness: Narratives of elderly people

with depression. Journal of aging studies. 2012;26(4):410-8.

Shing CM, Adams MJ, Fassett RG, Coombes JS. Nutritional compounds influence tissue factor

expression and inflammation of chronic kidney disease patients in vitro. Nutrition. 2011;27(9.72-967:)

Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Improved HPLC method for the determination of

curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Journal of Agricultural and Food Chemistry.

;50(13):3668-72.

Ataie A, Sabetkasaei M ,Haghparast A, Moghaddam AH, Ataee R, Moghaddam SN. Curcumin exerts

neuroprotective effects against homocysteine intracerebroventricular injection-induced cognitive impairment

and oxidative stress in rat brain. Journal of medicinal food. 2010;13(4):821-6.

Abdollahzad H, Eghtesadi S, Nourmohammadi I, Khadem-Ansari M, Nejad-Gashti H, Esmaillzadeh A.

Effect of vitamin C supplementation on oxidative stress and lipid profiles in hemodialysis patients .International

journal for vitamin and nutrition research. 2009;79(56):281-7.

Dairam A, Fogel R, Daya S, Limson JL. Antioxidant and iron-binding properties of curcumin,

capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. Journal of Agricultural and Food

Chemistry. 2008;56(9):3350-6.

Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic

cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis International. 2004;8(2):118-

Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Biofactors. 2013;39(1):69-77.

Shukla PK, Khanna VK, Ali MM, Khan MY, Srimal RC. Anti-ischemic effect of curcumin in rat brain.

Neurochemical research. 2008;33(6):1036-43.

Moreillon JJ, Bowden RG, Deike E, Griggs J, Wilson R, Shelmadine B, et al. The use of an anti-

inflammatory supplement in patients with chronic kidney disease. Journal of Complementary and Integrative

Medicine. 2013;10(1):143-52.

Moreillon JJ, Bowden RG, Deike E, Griggs J, Wilson R, Shelmadine B, et al. The use of an anti-

inflammatory supplement in patients with chronic kidney disease. Journal of Complementary and Integrative

Medicine. 2013;10(1):143-52.

Buyuklu M, Kandemir FM, Ozkaraca M, Set T, Bakirci EM, Topal E. Protective effect of curcumin

against contrast induced nephropathy in rat kidney: what is happening to oxidative stress, inflammation,

autophagy and apoptosis. Eur Rev Med Pharmacol Sci. 2014;18(4):461-70.